Navigation Links
MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer
Date:2/20/2008

UNION CITY, Calif., Feb. 20 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced the appointment of Joel Naor, M.D., M.Sc., MBA, as the company's chief medical officer. With broad expertise in the clinical development of therapeutics for ocular diseases and conditions, Dr. Naor will play a key role in MacuSight's ongoing advancement of its sirolimus program, as well as the company's overall scientific direction. MacuSight is currently developing its proprietary sirolimus product for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as various additional ocular diseases and conditions.

Formerly, as a senior medical director at Allergan, Inc., Dr. Naor was a key contributor to the medical and scientific direction of the company's two lead retina programs. In his role as the global project team leader for Allergan's POSURDEX(R) program, Dr. Naor oversaw a multifunctional team with responsibilities that spanned clinical development, regulatory, CMC and marketing. Most recently, he served on Allergan's global medical affairs group as a medical director, retina. Prior to his work with Allergen, Dr. Naor was a director of clinical research at QLT, Inc. where he served as a clinical lead on the global project team for Visudyne(R) (verteporfin for injection).

"Through his work at both Allergan and QLT, Joel has gained valuable experience and strategic insight related to the successful advancement of novel ocular therapeutics through clinical trials," stated David A. Weber, Ph.D., president and chief executive officer of MacuSight. "It is this expertise that makes him an ideal fit for MacuSight as we work to aggressively and successfully advance our sirolimus program through clinical development and toward the market. We are excited to have Joel as part of the team and look forward to the key contributi
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Veteran Bariatric Surgeon Expands Services to Solano County
2. Tahitian Noni International Expands HIRO(TM) Beverage Line With Super Fruits Sparkling Black Currant
3. Convera(R) Expands Advanstar OnLine Business to Vertical Search Covering Pharmaceutical Industry Applications
4. Hondros College Expands School of Nursing to Columbus and Dayton; Students Can Begin LPN Education Almost Immediately
5. Beryl Expands Leadership Team, Adds Senior VP of Product Management and Marketing
6. Anthem Blue Cross and Blue Shield Expands Network of Hospitals to Serve Hoosier Healthwise Members
7. Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
8. HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora, Ontario Wal-Mart Store # 5778
9. HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056
10. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
11. SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)... Freeze-drying of biopharmaceuticals to be ava... facility. , Toronto, ON...dent and CEO of Therapure Biopharma Inc. today ann...mmercial scale pharmaceutical grade freeze dryer a...(lyophilization) available for contract manufactur...
(Date:11/8/2009).... 7 Today, the House of... Dahlkemper, Smith, Ellsworth and Lipinski amendme... (H.R. 3962). The amendment maintains the current ...and for benefits packages that include abortion. I...ve affordability credits and those who do not, can...
(Date:11/8/2009).... 7 USAction this eveni...r America Act, which will make health care more af...ccountable and increase access to health care for ..., "Teddy Roosevelt, FDR and Harry Truman would be...ey. "Today,s vote ranks among our country,s proude...
(Date:11/8/2009).... 8 The following was r...n Rescue Insurrecta Nex. ,, Mr. Terry and his ...ing to keep child-killing by abortion out of any h...: "This is a great first step to victory -- a touc... fighting ahead of us. Our rejoicing must be tempe...
(Date:11/8/2009)...ouse Passage of Health Care Reform Bill ,, Cr...ove coverage for all Americans ,, BALTIMORE, N...t the United States House of Representatives passe...ld strengthen Medicare for seniors and end discrim...s of Americans out of affordable health coverage. ...
Breaking Medicine News(10 mins):Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3
...LL, N.C., Feb. 27 Effective communication of,clin...compound into a,blockbuster brand. How, when, and ...trials must be delivered -- these are some of the ...arking report by Best Practices, LLC,presents how ...
...pansion Comes a Year Early to Help Combat Vets, P...s Dr. James B. Peake today said an expansion by th...enters, which provide readjustment,counseling and ...xt two years. Fifteen of those centers are already...
...Based Vaccination Programs Using FluMist(R) May Se...ers of Eligible Children -, GAITHERSBURG, Md, Feb...nfluenza Virus Vaccine Live, Intranasal), today la...recommendations for routine seasonal influenza vac...
...domide, a drug blamed in the 1950s for causing bir...ffective treatment for women with recurrent ovaria... of Minnesota Cancer Center researcher., Levi Down... current issue of the journal Cancer. Downs is an...
...gton, DC, February 27, 2008 -- The Association for...gy (APIC) today announced that it has been selecte...o participate in a statewide effort to reduce heal...lthcare-Associated Infection Prevention Initiative...
...S, Ill., Feb. 27 With a persistent new strain,of ...ed to be more,assertive to help keep the workplace...CCH, a leading provider of human resources and emp...rs (54 percent) send,workers back home if they sho...
Other Medicine News:Health News:Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams 2Health News:VA Has Added 20 New Vet Centers 2Health News:MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations 2Health News:MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations 3Health News:MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations 4Health News:U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer 2Health News:CCH Outlines 10 Steps to Keeping the Workplace Healthy in the Height of Flu Season 2Health News:CCH Outlines 10 Steps to Keeping the Workplace Healthy in the Height of Flu Season 3Health News:CCH Outlines 10 Steps to Keeping the Workplace Healthy in the Height of Flu Season 4
(Date:11/6/2009)...ov. 6 In consultation with the U.S...mer Healthcare, Division of McNEIL-PPC, Inc., is i...f product lots of TYLENOL® Arthritis Pain Cap...-OPEN CAP. McNeil is initiating the recall after i...ciated with these lots that led to a small number ...
(Date:11/6/2009)...ire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NY...pany, announced today that Paul Bisaro, Watson,s p... an overview and update of the Company,s business ...ence on Wednesday, November 11, 2009 at 12:00 pm E... be webcast live and can be accessed on Watson Pha...
(Date:11/6/2009)...e-FirstCall/ -- Roper Industries, Inc. (NYSE: RO...ve agreement to acquire Verathon, Inc., a leading ...thon Board of Directors has approved the transacti...ory approvals and closing conditions, including sh...g to be completed in early December. ,, Headqu...
Breaking Medicine Technology:McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3WomenHeart and P A D Coalition Join Forces to Educate Women about Peripheral Arterial Disease 56532 1WomenHeart and P A D Coalition Join Forces to Educate Women about Peripheral Arterial Disease 56532 2WomenHeart and P A D Coalition Join Forces to Educate Women about Peripheral Arterial Disease 56532 3Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 13932 1Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 13932 2Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 13932 3Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 13932 4Orexigen 28R 29 Therapeutics to Speak at Upcoming Conferences 13930 1
...d Selective MEK inhibitor with Favorable In Vitro ...es -, CARLSBAD, Calif., Oct. 8 Ardea Biosciences...e discovery and,development of small-molecule ther...er and inflammatory diseases, today announced that...19, will be presented at,the American Association ...
.... 5 Wyeth,Pharmaceuticals, a division of Wyeth (N...se 3 studies, which showed that bazedoxifene/conju... hot flashes in symptomatic,postmenopausal women b...ese,data, presented at the North American Menopaus...fene/conjugated estrogens improved symptoms of,vul...
Other Medicine Technology:Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 3Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 2Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 3Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 4
...inding (ACB®) Test is a clinical chemistry ass...;) by measuring the cobalt binding capacity of alb...n the early 1990s, IMA is produced when circulatin... the heart. During ischemia, the N-terminus of alb...
...es kits that quantitatively measure two important ... (a). An elevated serum or plasma homocysteine lev...ent risk factor for cardiovascular disease. And nu...ed elevated levels of Lp(a) with increased risk of...
...or autoimmune testing feature single-well ANA scre...ex tests including dsDNA, and 6 individual ENA kit...-1. In addition, our autoimmune ELISA family inclu... IgG, IgM), Thyroglobulin, Thyroid Microsomal, MPO...
...or autoimmune testing feature single-well ANA scre...ex tests including dsDNA, and 6 individual ENA kit...-1. In addition, our autoimmune ELISA family inclu... IgG, IgM), Thyroglobulin, Thyroid Microsomal, MPO...
Medicine Products: